Intriguingly, despite known presence of activating NRAS and MAP2K1 mutations, phospho-ERK1/2 (pERK) expression (by IHC) was largely absent from tumor cells, except when located at or immediately beneath the tumor margin (Fig. 3g), suggesting MAPK activation in response to factors originating near the tumor surface. Here, NRAS is linked to neoplasm.